Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.